Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 16/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 6/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.35 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24065732 | 0.87 | HSD11B1 (0.36) | NR3C1RXRARXRBRXRG | |
| SCHEMBL25001131 | 0.81 | NR3C1 (0.40) | NR3C1NR3C2RXRARXRBRXRG | |
| SCHEMBL18714324 | 0.81 | RXRA (0.41) | NR3C1RXRARXRBRXRG | |
| SCHEMBL25001119 | 0.79 | NR3C1 (0.40) | NR3C1NR3C2RXRARXRBRXRG | |
| SCHEMBL22147201 | 0.78 | SMN1; SMN2 (0.37) | — | |
| SCHEMBL18672381 | 0.77 | ALDH1A1 (0.47) | NR3C1RXRARXRBRXRG | |
| SCHEMBL25722708 | 0.76 | NR1H4 (0.38) | NR3C1RXRARXRBRXRG | |
| SCHEMBL6371363 | 0.75 | TDP1 (0.47) | RXRARXRBRXRG | |
| SCHEMBL19431079 | 0.73 | NR3C1 (0.40) | NR3C1NR3C2 | |
| SCHEMBL23869744 | 0.72 | ALDH1A1 (0.47) | NR3C1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597378-B2 | Tetrahydroisoquinolines for use as MOR/NOP dual agonists | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2020-03-24 | — | — | US | disclosed |
| US-20190077786-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597378-B2 | Tetrahydroisoquinolines for use as MOR/NOP dual agonists | OPRL1, OPRM1, OPRK1 | NR3C1 234/4885NR3C2 261/4885HCRTR1 46/4885 |
| US-20190077786-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | OPRM1, OPRL1, OPRK1 | NR3C1 246/4885NR3C2 194/4885HCRTR1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.